rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

ANI Pharmaceuticals, Inc.

ANIP · Nasdaq

Health CarePharmaceuticalsNot moving yet

ANIP stood above a rising 150-day average in 11 of the last 52 weekly readings, and has been out of that trend for the last 39 weeks. It is 7.0% below that average now. Pharmaceuticals: 31% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 39
Industry in uptrend
31% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$28.1M
Officials’ trades on record
2
Institutions holding
283 (+27)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 11 of 52 weeks.

17 Apr – 16 Oct
26%36%46%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$34.4M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

2 disclosed lines: House 0, Senate 0, executive 2; 1 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k30 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k13 Apr 2026filed 1 Jul 2026

Insiders

Buy orders, 12 months0
Sale orders, 12 months48
Buyers · sellers0 · 12
WhoDidSharesTraded
Nikhil LalwaniPRESIDENT & CEOsold5,400at $71.8915 Oct 2026filed 16 Oct 2026
Meredith CookSR. VP, GENERAL COUNSEL & SEC.sold500at $73.5913 Oct 2026filed 13 Oct 2026
Stephen P. CareySVP & CFOsold2,850at $73.0029 Sep 2026filed 30 Sep 2026
Nikhil LalwaniPRESIDENT & CEOsold5,400at $71.0015 Sep 2026filed 16 Sep 2026
Meredith CookSR. VP, GENERAL COUNSEL & SEC.sold500at $70.7914 Sep 2026filed 14 Sep 2026
Jeanne ThomaDirectorsold1,000at $71.5311 Sep 2026filed 14 Sep 2026
Stephen P. CareySVP & CFOsold2,850at $72.8031 Aug 2026filed 1 Sep 2026
Nikhil LalwaniPRESIDENT & CEOsold5,400at $74.3025 Aug 2026filed 26 Aug 2026
Meredith CookSR. VP, GENERAL COUNSEL & SEC.sold500at $75.4813 Aug 2026filed 13 Aug 2026
Ori GutwergSVP, GENERICSsold3,162at $77.0010 Aug 2026filed 11 Aug 2026
Stephen P. CareySVP & CFOsold2,850at $81.3629 Jul 2026filed 30 Jul 2026
Meredith CookSR. VP, GENERAL COUNSEL & SEC.sold500at $81.8413 Jul 2026filed 14 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders283+27 on the quarter
New · exited54 · 26
Reported value$1.9B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20262,958,646$244.9M+211,154+7.7%
Soleus Capital Management, L.P.added · filed 11 Aug 2026867,760$71.8M+47,517+5.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026838,224$69.4M+15,160+1.8%
STATE STREET CORPadded · filed 7 Aug 2026831,647$68.9M+60,060+7.8%
TANG CAPITAL MANAGEMENT LLCunchanged · filed 14 Aug 2026707,500$58.6M00.0%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026623,463$51.6M+92,273+17.4%
AMERICAN CENTURY COMPANIES INCadded · filed 12 Aug 2026574,474$47.6M+382,898+199.9%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPreduced · filed 13 Aug 2026562,016$46.5M-2,344−0.4%
Global Alpha Capital Management Ltd.added · filed 13 Aug 2026558,003$46.2M+196,763+54.5%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026536,407$44.4M+47,206+9.6%
31 Mar 2023 – 30 Jun 2026
112195277Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Nikhil Lalwani Company insiderPRESIDENT & CEO · last 15 Oct 20261 · 11
Meredith Cook Company insiderSR. VP, GENERAL COUNSEL & SEC. · last 13 Oct 20260 · 36
Stephen P. Carey Company insiderSVP & CFO · last 29 Sep 20260 · 12
Jeanne Thoma Company insiderDirector · last 11 Sep 20262 · 2
Henry O. Gosebruch Company insiderDirector · last 19 Aug 20260 · 0
Ori Gutwerg Company insiderSVP, GENERICS · last 10 Aug 20260 · 8
Thomas Haughey Company insiderDirector · last 8 Jun 20264 · 2
Antonio R. Pera Company insiderDirector · last 21 May 20261 · 4
Matthew J. Leonard Company insiderDirector · last 21 May 20260 · 2
Renee P. Tannenbaum Company insiderDirector · last 21 May 20260 · 2
Patrick D. Walsh Company insiderDirector · last 13 May 20264 · 5
Thomas Andrew Rowland Company insiderSVP, HEAD - ESTABLISHED BRANDS · last 12 May 20260 · 3

Same industry

ABBV AbbVieLeading+20%
VTRS ViatrisLeading+16%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 202512.6%
Free cash flow marginFY 2025 · to 31 Dec 202519.4%
Return on capital employedFY 2025 · to 31 Dec 20259.6%
Cash conversionFY 2025 · to 31 Dec 2025236%
Debt to equityFY 2025 · to 31 Dec 20250.57×
Interest coverFY 2025 · to 31 Dec 20253.41×
Research spendFY 2025 · to 31 Dec 20255.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$285.6M
Free cash flowFY 2025 · to 31 Dec 2025$171.4M

Analyst forecasts

No analyst forecasts yet.